The Multiple Myeloma (MM) market is currently dominated by Velcade and Revlimid, and the market is set to undergo substantial growth between 2013 and 2023. The main drivers of growth will be the launch of monoclonal antibodies (mAbs) Empliciti and daratumumab, which will not only provide a new treatment option for MM patients, but will also lengthen the time between relapses, meaning that the duration of Revlimid and/or Velcade treatments will also be longer. Browse Full Report With TOC @ http://www.researchmoz.us/pharmapoint-multiple-myeloma-global-drug-forecast-and-market-analysis-to-2023-report.html
http://www.researchmoz.us/pharmapoint-multiple-myeloma-global-drug-forecast-and-market-analysis-to-2023-report.html
No comments:
Post a Comment